Brokerages Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Price Target at $40.80

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have earned an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $40.80.

Several brokerages recently issued reports on GMAB. Weiss Ratings reiterated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Genmab A/S from a “strong-buy” rating to a “buy” rating in a research note on Saturday. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Genmab A/S in a research note on Wednesday. Truist Financial raised their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Finally, Zacks Research upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $33.17 on Thursday. The stock has a market capitalization of $21.30 billion, a price-to-earnings ratio of 16.67, a PEG ratio of 1.85 and a beta of 0.98. The business has a 50-day moving average of $27.95 and a 200-day moving average of $23.36. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $33.65.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The company had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently bought and sold shares of GMAB. GAMMA Investing LLC lifted its position in Genmab A/S by 1,465.3% during the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company’s stock worth $656,000 after acquiring an additional 31,343 shares during the last quarter. QRG Capital Management Inc. lifted its position in Genmab A/S by 213.7% during the first quarter. QRG Capital Management Inc. now owns 74,847 shares of the company’s stock worth $1,465,000 after acquiring an additional 50,990 shares during the last quarter. Blue Trust Inc. lifted its position in Genmab A/S by 169.9% during the first quarter. Blue Trust Inc. now owns 7,413 shares of the company’s stock worth $145,000 after acquiring an additional 4,666 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its position in Genmab A/S by 20.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 249,468 shares of the company’s stock worth $4,885,000 after acquiring an additional 42,361 shares during the last quarter. Finally, DAVENPORT & Co LLC lifted its position in Genmab A/S by 21.1% during the first quarter. DAVENPORT & Co LLC now owns 31,679 shares of the company’s stock worth $620,000 after acquiring an additional 5,529 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.